Drugs / KLH
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05025488 Background | Apr 2023 → Mar 2027 expected | essential thrombocythemia, myelofibrosis | Marina Kremyanskaya | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KLH | “ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only).” NCT05025488 ↗ |
| Modality | Peptide | “KLH as helper peptide” NCT05025488 ↗ |